Please provide your email address to receive an email when new articles are posted on . Mean maximum ADAMTS13 activity after recombinant ADAMTS13 exceeded 100%. Markedly fewer patients receiving ...

Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six ...

Researchers from the Second Affiliated Hospital of Nanjing Medical University, et al. have published a case report entitled "Acquired immune thrombotic thrombocytopenic purpura (TTP) associated with ...

Thanks to a Takeda approval Thursday, patients now have a drug to tackle a rare inherited blood clotting disorder. The U.S. FDA has given a green light to Takeda’s Adzynma, the first recombinant ...

Two bleeding disorder treatments for both chronic and acute conditions, Qfitlia and Cablivi, have been approved in China.

Judicious use of caplacizumab (Cablivi) can reduce the risk of severe bleeding and help manage costs associated with the therapy in patients living with thrombotic thrombocytopenic purpura (TTP). The ...

Megakaryocytes, which are derived from hematopoietic stem cell precursors in bone marrow, form and release platelets; these circulate in the blood for 8 to 10 days before they are removed by hepatic ...

China NMPA approves Sanofi’s Qfitlia for haemophilia and Cablivi for acquired thrombotic thrombocytopenic purpura: Paris Friday, December 12, 2025, 09:00 Hrs [IST] The National ...

Sanofi secures China approvals for Qfitlia and Cablivi, expanding its rare hematology portfolio with new options for ...

Every day, Sanofi employees work to chase the miracles of science and improve people’s lives by asking themselves “what if?” Our work is rooted in scientific curiosity centered on the question: What ...